Iodochlorhydroxyquin, in combination with hydrocortisone (Vioform-Hydrocortisone [CIBA]) is widely available and widely used for a variety of skin disorders because of its anti-inflammatory and broad chemotherapeutic efficacy against bacterial, fungal, and monilial agents. Its application to other-than-normal skin could conceivably result in optic atrophy.1 In view of this fact, its continued presence on the market should be brought into question. I plan to try to sharpen my dermatologic acumen and prescribe more specific therapy for the dermatoses I see.

This content is only available via PDF.
You do not currently have access to this content.